Wikipedia

SB-431542

This is an old revision of this page, as edited by Dmitry Dzhagarov (talk | contribs) at 20:09, 15 July 2015. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7. It also suppressed the TGF-beta-induced proliferation of osteosarcoma cells in humans. [1] The treatment with SB431542 is a robust, clinically applicable, and efficient system for generating mesenchymal stem/stromal cells (MSCs) from human iPSCs[2].

SB-431542
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
  • InChI=1S/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26)
    Key: FHYUGAJXYORMHI-UHFFFAOYSA-N
  • InChI=1/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26)
    Key: FHYUGAJXYORMHI-UHFFFAOYAN
  • NC(=O)c1ccc(cc1)c2nc(c3ccc4OCOc4c3)c([nH]2)c5ccccn5
Properties
C22H16N4O3
Molar mass 384.4
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

References

  1. ^ Laping, NJ (2002). "Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542". Molecular Pharmacology. 62 (1): 58–64. doi:10.1124/mol.62.1.58. PMID 12065755. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  2. ^ Chen Y S, Pelekanos R A., Ellis R L., et al and Nicholas M. Fisk (2012). Small Molecule Mesengenic Induction of Human Induced Pluripotent Stem Cells to Generate Mesenchymal Stem/Stromal Cells Stem Cells Trans Med., 1(2), 83-95 DOI:10.5966/sctm.2011-0022
Retrieved from "https://en.wikipedia.org/w/index.php?title=SB-431542&oldid=671605850"